You are here

Home » Content

Diyabetik Otonom Nöropati’de Güncel Tanı ve Tedavi Yaklaşımları

Current Diagnosis and Treatment Approaches in Diabetic Autonomic Neuropathy

Journal Name:

  • Abant Tıp Dergisi

Publication Year:

  • 2017
DOI: 
10.5505/abantmedj.2017.48658

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Diabetic autonomic neuropathy is the most common and troublesome complication of diabetes mellitus. Though involvement of the autonomic nervous system is generally diffuse, symptoms may be confined to a single target organ or organ system. Complications of diabetic autonomic neuropathy contribute greatly to the morbidity, mortality, and reduced quality of life of the person with diabetes and are the major source of increased costs of caring for the diabetic patient. Factors in the pathogenesis of these complications are altered metabolism, vascular insufficiency, loss of growth factor trophism, and autoimmune destruction of nerves in a visceral and cutaneous distribution. The clinical manifestations and the complications of diabetic autonomic neuropathy are reviewed. Future therapeutic strategies that are developed from a better understanding of the pathogenetic processes underlying this disorder can be directed at the cause rather than the manifestations. There are studies in progress that suggest that autonomic nerves can be induced to regenerate, and the future for patients with diabetic autonomic neuropathy is brighter.
Bookmark/Search this post with
Abstract (Original Language): 
Diyabetik otonom nöropati, diyabetin en sık ve en sıkıntı verici komplikasyonudur. Otonom sinir sistemi (OSS) tutulumu genellikle diffuz olsa da, semptomlar tek bir hedef organ veya sistem ile sınırlı olabilir.Diyabetik otonom nöropatinin komplikasyonları mortalite ve morbiditede artışa, yaşam kalitesinde azalmaya ve diyabetik hastaların tedavi maliyetinde artışa sebep olmaktadır.Bu komplikasyonların patogenezindeki faktörler; metabolizmada değişme, vasküler yetersizlik, büyüme faktörlerinin trofizminde kayıp ve viseral ve kutanöz sinirlerde otoimmun destriksiyon olarak sıralanabilir. Diyabetik otonom nöropatinin komplikasyonları ve klinik manifestasyonları ile ilgili yayınlar mevcuttur. Gelecekte, hastalığın altında yatan patolojik sürecin daha iyi anlaşılması ile birlikte, tedaviler manifestasyona değil neden yönelik olabilir. Halen sürmekte olan ve otonom sinirlerin rejenerasyonunun indüklenebilir olduğu bir takım çalışmaların varlığı, diyabetik otonom nöropati hastalarının tedavisinde ümit vericidir.
FULL TEXT (PDF): 
PDF icon arastirmax-diyabetik-otonom-noropatide-guncel-tani-tedavi-yaklasimlari.pdf
  • 3
129
133
  • Turkish

REFERENCES

References: 

1. Vinik AI, Erbas T, Pfeifer MA, Feldman EL, Stevens MJ,
Russell JW. Diabetic autonomic neuropathy. In: Porte D,
Sherwin RS, Baron A, eds. Ellenberg & Rifkin's Diabetes
Mellitus. 6th ed. New York: McGraw Hill; 2003:789-804.
2. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic
autonomic neuropathy. Diabetes Care 2003;26:1553-
1579
3. Ziegler D. Cardiovascular autonomic neuropathy: clinical
manifestations and measurement. Diabetes Reviews
1999;7: 300-315.
4. Kahn J, Zola B, Juni J, Vinik AI. Decreased exercise heart
rate in diabetic subjects with cardiac autonomic
neuropathy. Diabetes Care 1986;9:389-394
5. Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE.
Natural history of diabetic gastroparesis. Diabetes Care
1999; 22:503-507.
6. Lysy J, Israeli E, Goldin E. The prevalence of chronic
diarrhea among diabetic patients. Am J Gastroenterol
1999;94: 2165-2170.
7. Stansberry KB, Peppard HR, Babyak LM, Popp G, McNitt
PM, Vinik AI. Primary nociceptive afferents mediate the
blood flow dysfunction in non-glabrous (hairy) skin of
type 2 diabetes: a new model for the pathogenesis of
microvascular dysfunction. Diabetes Care 1999;22:1549-
1554.
8. Vinik AI, Erbas T, Park TS, Pierce KK, Stansberry KB.
Methods for evaluation of peripheral neurovascular
dysfunction. Diabetes Technol Ther 2001;3:29-50
9. Vinik A, Erbas T, Stansberry K. Gastrointestinal,
genitourinary, and neurovascular disturbances in
diabetes. Diabetes Reviews 1999;7:358-378.
10. Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman
MA, Rimm EB. Association of type and duration of
diabetes with erectile dysfunction in a large cohort of
men. Diabetes Care 2002;25:1458-1463.
11. Bradley WE. Diagnosis of urinary bladder dysfunction in
diabetes mellitus. Ann Intern Med 1980;92:323-326.
12. Shaw JE, Parker R, Hollis S, Gokal R, Boulton AJ. Gustatory
sweating in diabetes mellitus. Diabet Med 1996;13:1033-
1037.
13. Cryer PE. Hypoglycemia-associated autonomic failure in
diabetes. Am J Physiol Endocrinol Metab
2001;281:E1115-E1121.
14. DCCT Research Group. The effect of intensive diabetes
therapy on measures of autonomic nervous system
function in the Diabetes Control and Complications Trial
(DCCT). Diabetologia 1998;41:416-423.
15. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified
multifactorial intervention in patients with type 2
diabetes mellitus and microalbuminuria: the Steno type 2
randomised study. Lancet 1999;353:617-622.
16. Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic
acid in the treatment of diabetic polyneuropathy in
Germany: current evidence from clinical trials. Exp Clin
Endocrinol Diabetes 1999;107:421-430.
17. Ebbehoj E, Poulsen PL, Hansen KW, Knudsen ST,
Molgaard H, Mogensen CE. Effects on heart rate
variability of metoprolol supplementary to on going ACEinhibitor
treatment in type I diabetic patients with
abnormal albuminuria. Diabetologia 2002;45:965-975.
18. Kontopoulos AG, Athyros VG, Didangelos TP, et al. Effect
of chronic quinapril administration on heart rate
variability in patients with diabetic autonomic
neuropathy. Diabetes Care 1997;20:355-361.
19. Malik RA, Williamson S, Abbott C, et al. Effect of
angiotensin-converting-enzyme (ACE) inhibitor
trandolapril on human diabetic neuropathy: randomised
double-blind controlled trial. Lancet 1998;352:1978-1981.
20. Richardson D, Vinik A. Etiology and treatment of erectile
failure in diabetes mellitus. Curr Diab Rep 2002;2:501-
509.
21. Maleki D, Locke GR III, Camilleri M, et al. Gastrointestinal
tract symptoms among persons with diabetes mellitus in
Araç E
Abant Med J 2017;6(3):129-133 133
the community. Arch Intern Med 2000;160:2808-2816.
22. Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S.
Comparison of metoclopramide and erythromycin in the
treatment of diabetic gastroparesis. Diabetes Care
1993;16:1511-1514.
23. Janssens J, Peeters TL, Vantrappen G, et al. Improvement
of gastric emptying in diabetic gastroparesis by
erythromycin. Preliminary studies. N Engl J Med
1990;322:1028-1031.
24. Shaw JE, Abbott CA, Tindle K, Hollis S, Boulton AJ. A
randomized controlled trial of topical glycopyrrolate, the
first specific treatment for diabetic gustatory sweating.
Diabetologia 1997;40:299-301.
25. Restivo DA, Lanza S, Patti F, et al. Improvement of
diabetic autonomic gustatory sweating by botulinum
toxin type A. Neurology 2002;59:1971-1973.

Thank you for copying data from http://www.arastirmax.com